Evaluating rotavirus vaccination in England and Wales. Part II. The potential cost-effectiveness of vaccination. (Q53198731)

12 May 2018

title

Evaluating rotavirus vaccination in England and Wales. Part II. The potential cost-effectiveness of vaccination. (English)

1 reference

12 May 2018

cost-effectiveness analysis

main subject

1 reference

Jit M

1

1 reference

12 May 2018

Edmunds WJ

series ordinal

2

1 reference

12 May 2018

language of work or name

English

0 references

publication date

13 March 2007

1 reference

12 May 2018

published in

Vaccine

1 reference

12 May 2018

volume

25

1 reference

12 May 2018

issue

20

1 reference

12 May 2018

page(s)

3971-3979

1 reference

12 May 2018

Global Illness and Deaths Caused by Rotavirus Disease in Children

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.02.070

Estimating the number of deaths with rotavirus as a cause in England and wales

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.02.070

Safety and Efficacy of an Attenuated Vaccine against Severe Rotavirus Gastroenteritis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.02.070

Safety and efficacy of a pentavalent human-bovine (WC3) reassortant rotavirus vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.02.070

Variations in population health status: results from a United Kingdom national questionnaire survey

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.02.070

EstimatingHaemophilus influenzaeType b Vaccine Effectiveness in England and Wales by Use of the Screening Method

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.02.070

What can analysis of calls to NHS direct tell us about the epidemiology of gastrointestinal infections in the community?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.02.070

The study of infectious intestinal disease in England: socio-economic impact

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.02.070

Economic evaluation of rotavirus vaccinations in Finland: randomized, double-blind, placebo-controlled trial of tetravalent rhesus rotavirus vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.02.070

Cost effectiveness of rotavirus vaccination in Australia.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.02.070

National Institute for Clinical Excellence and its value judgments

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.02.070

The promise of new rotavirus vaccines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.02.070

Burden of rotavirus disease in European Union countries

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.02.070

Cost-effectiveness analysis of a rotavirus immunization program for the United States

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.02.070

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1016/J.VACCINE.2007.02.070

1 reference

12 May 2018

PubMed ID

17400341

1 reference

12 May 2018